Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 44-51

  Scaruffi, Paola ^a   Morandi, Fabio ^b   Gallo, Fabio ^a   Stigliani, Sara ^a   Parodi, Stefano ^a,b   Moretti, Stefano ^c   Bonassi, Stefano ^d   Fardin, Paolo ^b   Garaventa, Alberto ^b   Zanazzo, Giulio ^e   Pistoia, Vito ^b   Tonini, Gian Paolo ^a   Corrias, Maria Valeria ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITÉ PARIS DAUPHINE   (France)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e Burlo Garofalo ^*  (Italy)

Author keywords

Bone marrow microenvironment; CXCL12; Gene expression profiling; IFN signature; Metastasis; Neuroblastoma

Indexed keywords

HISTONE; INTERFERON; MESSENGER RNA; METALLOTHIONEIN; NORADRENALIN; SIFALIMUMAB; STROMAL CELL DERIVED FACTOR 1; ZINC FINGER PROTEIN;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER PROGNOSIS; CELL ADHESION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; ERYTHROCYTE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; METASTASIS; NEUROBLASTOMA; NUCLEOSOME; PRIORITY JOURNAL; RNA EXTRACTION; THROMBOCYTE; TUMOR MICROENVIRONMENT;

ADOLESCENT; BONE MARROW; BONE MARROW CELLS; BONE MARROW NEOPLASMS; CHEMOKINE CXCL12; CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERFERONS; ITALY; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REGISTRIES; RETROSPECTIVE STUDIES; TUMOR MICROENVIRONMENT;

EID: 84861206644     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23339     Document Type: Article

References (45)

1. Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (INRG) classification system: An INRG task force report. J Clin Oncol 2009; 27: 289-297.
2. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in european children (1978-1997): Report from the automated childhood cancer information system project. Eur J Cancer 2006; 42: 2081-2091.
3. Michigami T, Ihara-Watanabe M, Yamazaki M, et al. Receptor activator of nuclear factor kappab ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001; 61: 1637-1644.
4. Granchi D, Amato I, Battistelli L, et al. In vitro blockade of receptor activator of nuclear factor-kappab ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 2004; 111: 829-838.
5. Fukaya Y, Shimada H, Wang LC, et al. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008; 283: 18573-18581.
6. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-4757.
7. Nevo I, Sagi-Assif O, Meshel T, et al. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol Lett 2004; 92: 163-169.
8. Russell HV, Hicks J, Okcu MF, et al. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 2004; 39: 1506-1511.
9. Airoldi I, Raffaghello L, Piovan E, et al. CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: Clinical implications. Clin Cancer Res 2006; 12: 77-82.
10. Carlisle AJ, Lyttle CA, Carlisle RY, et al. CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Mol Cancer 2009; 8: 126.
11. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
12. Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with neuroblastoma between 1979 and 2005: A report of the Italian Neuroblastoma Registry. J Clin Oncol 2010; 28: 2331-2338.
13. Corrias MV, Parodi S, Haupt R, et al. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. Br J Cancer 2008; 98: 263-269.
14. Dennis G, Jr., Sherman BT, Hosack DA, et al. David: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
15. Samarajiwa SA, Forster S, Auchettl K, et al. Interferome: The database of interferon regulated genes. Nucleic Acids Res 2009; 37: D852-D857.
16. Corrias MV, Haupt R, Carlini B, et al. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer 2011; Epub ahead of print.
17. Corrias MV, Pistorio A, Cangemi G, et al. Detection of cell-free RNA in children with neuroblastoma and comparison with that of whole blood cell RNA. Pediatr Blood Cancer 2010; 54: 897-903.
18. Lefever S, Hellemans J, Pattyn F, et al. Rdml: Structured language and reporting guidelines for real-time quantitative PCR data. Nucleic Acids Res 2009; 37: 2065-2069.
19. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
21. Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: Possible role in progenitor survival. Blood 2000; 95: 756-768.
22. Meier R, Muhlethaler-Mottet A, Flahaut M, et al. The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. PLoS ONE 2007; 2: e1016.
23. Beiske K, Burchill SA, Cheung IY, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and qRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009; 100: 1627-1637.
24. Lazo JS, Basu A. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Semin Cancer Biol 1991; 2: 267-271.
25. Basu A, Lazo JS. A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. Toxicol Lett 1990; 50: 123-135, discussion 121-122.
26. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628.
27. Jonasch E, Haluska FG. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55.
28. Airoldi I, Meazza R, Croce M, et al. Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity. Br J Cancer 2004; 90: 2210-2218.
29. Einav U, Tabach Y, Getz G, et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 2005; 24: 6367-6375.
30. Croce M, Meazza R, Orengo AM, et al. Immunotherapy of neuroblastoma by an interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008; 57: 1625-1634.
31. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: Immunotherapeutic implications. Neoplasia 2006; 8: 833-842.
32. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.
33. Kim SH, Gunnery S, Choe JK, et al. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 2002; 21: 8741-8748.
34. Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68: 927-936.
35. Martin DN, Boersma BJ, Yi M, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 2009; 4: e4531.
36. Degols G, Eldin P, Mechti N. ISG20, an actor of the innate immune response. Biochimie 2007; 89: 831-835.
37. Brodsky LI, Wahed AS, Li J, et al. A novel unsupervised method to identify genes important in the anti-viral response: Application to interferon/ribavirin in hepatitis C patients. PLoS ONE 2007; 2: e584.
38. Khodarev NN, Beckett M, Labay E, et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 2004; 101: 1714-1719.
39. Khodarev NN, Minn AJ, Efimova EV, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007; 67: 9214-9220.
40. Tsai MH, Cook JA, Chandramouli GV, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007; 67: 3845-3852.
41. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 2008; 105: 18490-18495.
42. Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev 2011; 240: 141-159.
43. Yao Y, Higgs BW, Richman L, et al. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: S6.
44. Mendez-Ferrer S, Lucas D, Battista M, et al. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452: 442-447.
45. Goodall AR, Danks K, Walker JH, et al. Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. J Neurochem 1997; 68: 1542-1552.